[LB] Late Breaking Symposium

[LB-4] SPTLC2 variants are associated with early-onset ALS and FTD due to aberrant sphingolipid synthesis

Hiroya Naruse^1,2, Hiroyuki Ishiura^1,3, Kayoko Esaki⁴, Jun Mitsui^1,2, Wataru Satake¹, Yuka Machino⁵, Yasumasa Kokubo⁶, Hirotoshi Hamaguchi⁷, Takeo Yoshikawa⁸, Shoji Tsuji⁹, Tatsushi Toda¹ (1.Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan, 2.Department of Precision Medicine Neurology, Graduate School of Medicine, The University of Tokyo, Japan, 3.Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan, 4.Department of Biotechnology and Life Sciences, Faculty of Biotechnology and Life Sciences, Sojo University, Japan, 5.Department of Neurology, National Hospital Organization Mie National Hospital, Japan, 6.Kii ALS/PDC Research Center, Graduate School of Regional Innovation Studies, Mie University, Japan, 7.Department of Neurology, Kita-Harima Medical Center, Japan, 8.Laboratory of Molecular Psychiatry, RIKEN Center for Brain Science, Japan, 9.Institute of Medical Genomics, International University of Health and Welfare, Japan)